Terazosin


Full Generic Medicine Info
Dosage/Direction for Use

Oral
Hypertension
Adult: As monotherapy or in combination with diuretics or other antihypertensive agents: Initially, 1 mg at bedtime, increased gradually at weekly intervals according to patient's response. Maintenance: 2-10 mg once daily. Max: 20 mg daily in 1 or 2 divided doses.

Oral
Benign prostatic hyperplasia
Adult: Initially, 1 mg at bedtime, increased gradually at weekly intervals according to patient's response. Maintenance: 5-10 mg once daily.
Administration
Terazosin: May be taken with or without food.
Contraindications
History of micturition syncope in the treatment of BPH.
Special Precautions
Patient with permanent erectile dysfunction and male impotence; severe coronary heart disease, pulmonary oedema due to aortic or mitral valve stenosis, high output cardiac insufficiency, right-sided cardiac insufficiency due to pulmonary embolism or pericardial effusion, left-sided cardiac insufficiency with low filling pressure. Hepatic impairment. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, drowsiness, and visual disturbances, if affected, do not drive or operate machinery. Monitoring Parameters Monitor blood pressure. Rule out prostate cancer before starting therapy for benign prostatic hyperplasia (BPH).
Adverse Reactions
Significant: First-dose hypotensive episodes (e.g. postural hypotension, syncope), orthostatic hypotension, priapism, floppy iris syndrome during cataract surgery, drowsiness, somnolence. Blood and lymphatic system disorders: Thrombocytopenia. Cardiac disorders: Palpitations, tachycardia, arrythmia, atrial fibriliation, chest pain. Endocrine disorders: Tinnitus. Eye disorders: Blurred vision, amblyopia, visual impairment, conjunctivitis. General disorders and administration site conditions: Asthenia, pyrexia, flu symptoms. Immune system disorders: Anaphylactoid reaction, angioedema, face oedema. Investigations: Weight increased, decreased hematocrit, decreased Hb, decreased WBC count, decreased total protein, decreased blood albumin. Metabolism and nutrition disorders: Peripheral oedema, oedema, Musculoskeletal and connective tissue disorders: Back pain, pain in extremity, neck pain, shoulder pain, gout, arthralgia, arthritis, joint disorders, myalgia. Nervous system disorders: Headache, paraesthesia, vertigo. Psychiatric disorders: Depression, nervousness, anxiety, insomnia. Renal and urinary disorders: Pollakiuria, UTI, urinary incontinence. Reproductive system and breast disorders: Libido decreased, erectile dysfunction. Respiratory, thoracic and mediastinal disorders: Nasal congestion, rhinitis, dyspnea, sinusitis, bronchitis, pharyngitis, cold symptoms, cough. Skin and subcutaneous tissue disorders: Pruritus, rash, hyperhidrosis. Vascular disorders: Vasodilation, epistaxis.
Overdosage
Symptoms: Acute hypotension. Management: Symptomatic and cardiovascular supportive treatment. Restore normal blood pressure and heart rate by keeping the patient in supine position. May give volume expanders in case of shock, then vasopressors, if necessary. Monitor renal function.
Drug Interactions
Increased adverse effects with ACE inhibitors (e.g. captopril, enalapril); and diuretics (e.g. hydrochlorothiazide, furosemide). Additive hypotensive effect with other antihypertensive agents. Increased concentration and significant hypotension with verapamil. Additive blood pressure lowering effect and symptomatic hypotension with phosphodiesterase type 5 (PDE5) inhibitors (e.g. sildenafil, tadalafil).
Action
Terazosin is an α1-adrenergic antagonist. It competitively inhibits post-synaptic α-receptors resulting to relaxation of peripheral blood vessels leading to gradual decrease in blood pressure followed by sustained antihypertensive action.
Onset: Antihypertensive effect: Within 15 minutes.
Duration: 24 hours.
Absorption: Rapidly and completely absorbed from the gastrointestinal tract. Bioavailability: Approx 90%. Time to peak plasma concentration: Approx 1 hour.
Distribution: Plasma protein binding: 90-94%.
Metabolism: Metabolised in the liver via demethylation and conjugation; undergoes minimal first pass metabolism.
Excretion: Via faeces (approx 60%, approx 20% as unchanged drug); urine (approx 40%, approx 10% as unchanged drug). Half-life: Approx 12 hours.
Storage
Oral: Store below 25°C. Protect from light and moisture.
CIMS Class
Drugs for Bladder & Prostate Disorders / Other Antihypertensives
ATC Classification
G04CA03 - terazosin ; Belongs to the class of alpha-adrenoreceptor antagonists. Used in the treatment of benign prostatic hypertrophy.
Disclaimer: This information is independently developed by CIMS based on terazosin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in